Welcome, Guest
Username: Password: Remember me
Adult Stem Cell News and Developments other than Cytori
  • Page:
  • 1

TOPIC: CUR continues to benefit from phase 1 results

CUR continues to benefit from phase 1 results 20 Mar 2014 17:10 #1437

  • myownhedgefund
  • myownhedgefund's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2865
  • Thank you received: 204
CUR at new highs today as they continues to benefit from phase 1 results in ALS released on Monday.
Phase 1, open lable and a nice move in the PPS.
Really makes you wonder why CYTX struggles. :bash:

onlinelibrary.wiley.com/doi/10.1002/ana.24113/full
The following user(s) said Thank You: Joncon63, d9dozrman

Please Log in or Create an account to join the conversation.

CUR continues to benefit from phase 1 results 21 Mar 2014 08:21 #1438

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116
I think the news that Novartis is looking to buy Gamida Cell for 600 Mio, brings new fantasy in the "engineering" SC companies I would think.

Novartis- Gamida

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.068 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites